Phoenix Biotechnology, Inc. Release: Despite Tight Financial Market, Company with Anti-Cancer Drug in Clinical Trial Raises $3.6 Million in Private Placement

SAN ANTONIO--(BUSINESS WIRE)--During a time of tight credit, record-breaking stock market plunges, and shell-shocked investors, anti-cancer drug development firm Phoenix Biotechnology, Inc., has just completed a private placement in which the company raised $3.6 million from individual investors.